Methods blog · Drug Repositioning & Network Medicine
COVID-CDRCOVID-CDR: network pharmacology for prioritising COVID-19 drug combinations
An online platform that maps drug targets onto the SARS-CoV-2–host interactome inside the human PPI network to find drug pairs acting through different, complementary pathways.
#COVID-19#combination therapy#network pharmacology#drug repositioning#interactome
SARS-CoV-2 pathology is multifactorial: viral replication, immune dysregulation, cytokine storm and tissue injury. A single repurposed drug rarely hits enough of these at once, which is why combination therapy is attractive. But how do you choose which two drugs to combine, from thousands of candidates, before any trial? COVID-CDR (COVID-19 Combinatorial Drug Repositioning), published in Patterns (Cell Press), offers a systematic, visual and quantitative answer.
The network-pharmacology view
Everything is placed on one map, the human protein–protein interaction (PPI) network:
- the SARS-CoV-2–host interactome, the human proteins that viral proteins bind or perturb;
- the primary targets of each candidate drug.
A drug is a plausible COVID-19 candidate if its targets sit close to the virus–host module in the network. A drug pair is a promising combination if the two drugs reach the disease module through different, potentially complementary routes, covering more of the pathology with less redundancy.
Prioritising pairs
A common way to formalise “close” in network medicine is the average shortest-path distance between a drug’s targets \(T\) and a disease module \(S\), for example
\[d(T,S) \;=\; \frac{1}{|T|}\sum_{t \in T} \min_{s \in S} \operatorname{dist}(t,s),\]compared against randomised target sets to obtain a z-score. COVID-CDR combines such topological relations between each drug’s targets and the virus–host interactome with multi-evidence drug–drug similarity from DrugSimDB. The goal is to surface pairs whose targets are individually relevant but mechanistically complementary rather than redundant.
What the platform offers
- Interactive visualisation of drug targets, viral–host proteins and their paths in the PPI network.
- Quantitative scores for individual drugs and drug pairs.
- Multi-evidence drug-pair similarity breakdowns (chemical, target, functional, pathway).
- Supporting information on each drug and pair, so clinicians and researchers can check the rationale.
To our knowledge COVID-CDR was the first online platform for systematic, pre-clinical in-silico investigation of combination therapies for COVID-19.
Data and follow-ups
The full resource is archived on Dryad (doi:10.5061/dryad.905qfttjm), with an earlier preprint on ChemRxiv. The same network-medicine logic led to our analysis of the cyclosporine–selinexor combination and the proposed NovexSyn.ai project on synergistic antivirals for new variants.